` MREO (Mereo Biopharma Group PLC) vs S&P 500 Comparison - Alpha Spread

MREO
vs
S&P 500

Over the past 12 months, MREO has underperformed S&P 500, delivering a return of -41% compared to the S&P 500's +14% growth.

Stocks Performance
MREO vs S&P 500

Loading
MREO
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MREO vs S&P 500

Performance Gap Between MREO and GSPC
HIDDEN
Show

Performance By Year
MREO vs S&P 500

Loading
MREO
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Mereo Biopharma Group PLC vs Peers

S&P 500
MREO
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Mereo Biopharma Group PLC
Glance View

Market Cap
318.3m USD
Industry
Biotechnology

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).

MREO Intrinsic Value
HIDDEN
Show
Back to Top